BR112018014161A2 - composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes - Google Patents

composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes

Info

Publication number
BR112018014161A2
BR112018014161A2 BR112018014161A BR112018014161A BR112018014161A2 BR 112018014161 A2 BR112018014161 A2 BR 112018014161A2 BR 112018014161 A BR112018014161 A BR 112018014161A BR 112018014161 A BR112018014161 A BR 112018014161A BR 112018014161 A2 BR112018014161 A2 BR 112018014161A2
Authority
BR
Brazil
Prior art keywords
resistant
soft tissue
tissue injury
biophotonic compositions
treating skin
Prior art date
Application number
BR112018014161A
Other languages
English (en)
Inventor
Salvaggio Alberto
Spaterna Andrea
Palumbo Piccionello Angela
Ohayon David
Bellini Francesco
Hébert Lise
Loupis Nikolaos
Piergallini Remigio
Original Assignee
Klox Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Klox Tech Limited filed Critical Klox Tech Limited
Publication of BR112018014161A2 publication Critical patent/BR112018014161A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/065—Light sources therefor
    • A61N2005/0651—Diodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

o presente documento descreve métodos e usos de composições biofotônicas que compreendem pelo menos um oxidante e pelo menos um cromóforo capaz de ativar o oxidante, em associação com um portador farmacologicamente aceitável para o uso no tratamento de ferimentos de pele e tecido mole que têm uma ou ambas infecções resistentes e não resistentes.
BR112018014161A 2016-01-11 2017-01-11 composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes BR112018014161A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662277286P 2016-01-11 2016-01-11
PCT/CA2017/050036 WO2017120674A1 (en) 2016-01-11 2017-01-11 Biophotonic compositions for treating skin and soft tissue wounds having either or both non-resistant and resistant infections

Publications (1)

Publication Number Publication Date
BR112018014161A2 true BR112018014161A2 (pt) 2018-12-11

Family

ID=59310477

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014161A BR112018014161A2 (pt) 2016-01-11 2017-01-11 composições biofotônicas para tratar ferimento de pele e tecido mole tendo uma ou ambas as infecções resistentes e não resistentes

Country Status (7)

Country Link
US (2) US11382977B2 (pt)
EP (1) EP3402524A4 (pt)
JP (1) JP2019501951A (pt)
AU (2) AU2017207536A1 (pt)
BR (1) BR112018014161A2 (pt)
CA (1) CA3010886A1 (pt)
WO (1) WO2017120674A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3710108A4 (en) * 2017-11-17 2021-08-18 Klox Technologies Limited MODULATION OF BIOPHOTONIC DOSING PLANS

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141321A (en) 1963-04-12 1964-07-21 Scovill Manufacturing Co Key retaining member
US4402959A (en) 1980-06-02 1983-09-06 Merck & Co., Inc. Antimicrobial compositions
US4430381A (en) 1982-06-25 1984-02-07 The Buckeye Cellulose Corporation Monocarboxylic acid antimicrobials in fabrics
US4625026A (en) 1982-12-30 1986-11-25 Biomeasure, Inc. 2-amino-4-oxo-tricyclicpyrimidines having antiviral activities against herpes simplex virus type II infections
US4533435A (en) 1984-06-07 1985-08-06 Microban Products Company Antimicrobial paper
US4736467A (en) 1986-12-24 1988-04-12 Burlington Industries, Inc. Operating room clothing system
US4855139A (en) 1987-01-20 1989-08-08 Med. Fab (Lafayette), Inc. Fungicidally active cellulosic textile compositions, or articles of manufacture
US5453275A (en) 1988-05-05 1995-09-26 Interface, Inc. Biocidal polymeric coating for heat exchanger coils
US5091102A (en) 1988-11-15 1992-02-25 Nordico, Inc. Method of making a dry antimicrobial fabric
US5069907A (en) 1990-03-23 1991-12-03 Phoenix Medical Technology Surgical drape having incorporated therein a broad spectrum antimicrobial agent
US5567372A (en) 1993-06-11 1996-10-22 Kimberly-Clark Corporation Method for preparing a nonwoven web containing antimicrobial siloxane quaternary ammonium salts
US5529769A (en) 1994-12-20 1996-06-25 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic compositions containing betulinic acid
US5894042A (en) 1996-02-26 1999-04-13 Technology Licensing Company Bacteriostatic coating of polymeric conduit
US5919554A (en) 1998-01-30 1999-07-06 Microban Products Company Antimicrobial fiberglass reinforced plastic composite
US6203805B1 (en) 1998-11-10 2001-03-20 Color Access, Inc. Topical compositions containing whey proteins
US6551608B2 (en) 2000-03-06 2003-04-22 Porex Technologies Corporation Porous plastic media with antiviral or antimicrobial properties and processes for making the same
JP4815752B2 (ja) 2004-04-01 2011-11-16 味の素株式会社 アミノ酸含有飲食品
US7598291B2 (en) 2004-09-02 2009-10-06 Marcel Nimni Methods and compositions for enhancing collagen and proteoglycan synthesis in the skin
KR101361379B1 (ko) 2005-04-13 2014-02-10 유키지루시 메그밀크 가부시키가이샤 영양 조성물
JP4033877B2 (ja) 2005-09-29 2008-01-16 株式会社ファンケル Ｉ型コラーゲン産生促進用組成物
US20080108681A1 (en) 2006-10-27 2008-05-08 Access Business Group International Llc Use of allantoin as a pro-collagen synthesis agent in cosmetic compositions
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
US7722904B2 (en) 2007-11-01 2010-05-25 Access Business Group International Llc Compositions and methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid
US20110086060A1 (en) 2008-04-11 2011-04-14 Florence Bidamant Novel compositions and their use
GB0810719D0 (en) 2008-06-11 2008-07-16 Dupont Teijin Films Us Ltd Polymeric film
GB0814105D0 (en) 2008-08-01 2008-09-10 Springdale Sustainable Develop Composition for accelerated production of collagen
PT3150210T (pt) * 2008-11-07 2019-09-04 Fb Dermatology Ltd Composição de rejuvenescimento cutâneo fotoativada e oxidativa
EA025022B1 (ru) 2009-07-17 2016-11-30 Клокс Текнолоджиз Инк. Антибактериальная композиция для ротовой полости
US20130281913A1 (en) 2012-04-20 2013-10-24 Klox Technologies Inc. Biophotonic compositions and methods for providing biophotonic treatment
RU2015113595A (ru) * 2012-09-14 2016-11-10 Клокс Текнолоджиз Инк. Комбинация хромофоров для биофотонных применений
MX366292B (es) * 2013-07-03 2019-07-04 Klox Tech Inc Composiciones biofotónicas que comprenden un cromóforo y un agente gelificante para el tratamiento de heridas.
EP3515497A4 (en) * 2016-09-23 2020-05-13 Klox Technologies Inc. BIOPHOTONIC COMPOSITIONS, METHODS AND KITS FOR INHIBITING AND DISRUPTIONING ORGANIC FILMS

Also Published As

Publication number Publication date
US20220296713A1 (en) 2022-09-22
WO2017120674A1 (en) 2017-07-20
US11382977B2 (en) 2022-07-12
CA3010886A1 (en) 2017-07-20
US20190022219A1 (en) 2019-01-24
EP3402524A1 (en) 2018-11-21
JP2019501951A (ja) 2019-01-24
AU2017207536A1 (en) 2018-07-26
EP3402524A4 (en) 2019-08-07
AU2022246411A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2019003636A1 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson.
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
CR20190252A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
BR112018012182A2 (pt) dispositivo para tratamento fotodinâmico
BR112018003845A2 (pt) auxiliares cirúrgicos com medicamentos afetados por materiais ativadores
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
CL2020001797A1 (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas.
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
AR096893A1 (es) Composición de un antagonista del factor de crecimiento del endotelio vascular (vegf, por sus siglas en inglés) para tratamiento de retinoterapia del prematuro
BR112017017502A2 (pt) dispositivo espaçador para o tratamento de um assento infectado no corpo humano
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CL2017001025A1 (es) Compuestos para usarse en el tratamiento antihelmíntico
BR112017015387A2 (pt) composição em gel tópica, método de tratamento de uma infecção da pele, composição em gel oftálmica, e, método de tratamento de uma afecção infecciosa do olho ou pálpebra
BR112015019395A2 (pt) composições e métodos para tratar e reparar tendões
BR112021017550A2 (pt) Métodos de tratamento da amiloidose al
BR112017006406A2 (pt) composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico
BR112021014854A2 (pt) Tratamento de lesões de pele e prurido em pacientes com prurigo nodularisis
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
UY33153A (es) Formulación tópica oftálmica de péptidos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: VETOQUINOL SA (FR)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]